Male Breast Reduction in Tallahassee Florida
Breasts in males are called genycomastia, a Greek word meaning "breasts looking similar to women's". 40-60% of men have breasts; many conditions can cause this phenomenon like medication and medical problems (alcohol use, marihuana and steroids), but in most of the cases the reason is not known. It can damage self-confidence and self esteem, therefore breast reduction can help.
The ideal candidates for the operation are men with genicomastia for at least a year long who have developed chest muscles and elastic skin. The surgery is not recommended for overweight men who can't loose weight using diet and exercise.
In case of extra breast tissue the surgeon will remove it through an invisible cut around the nipple or below the breast fold. Sometimes extra fat also removed using this method; the canula used for suction of the fat is inserted through the cut already made. When there is extra skin needs to be removed, the procedure may leave bigger scars.
If the extra tissue is fat, liposuction is performed. The cuts, 5-7 millimeters long, are made at the margins of the breast, from below and from the side. Sometimes small cut is made around the nipple. You may feel a vibration sensation, but no pain, if the procedure is done using local anesthetics. In extreme cases when there is large amounts of fat and tissue extracted, the extra skin needs to be removed, then a drainage tube usually left to prevent fluid collection.
Finally, incisions are closed and pressure bandages are placed.
Every operation has its risks. The risks include infection, bleeding, fluid collection, breast asymmetry (that needs to be corrected in additional surgery), scars, nipple distortion and permanent color changes of the skin.
After the surgery you may feel uncomfortable, regardless of the technique used. It can be treated with painkillers. Swelling and hemorrhage may appear in the area, to reduce the swelling you'll be instructed to wear a tight bandage around the chest for several weeks day and night. The breast will reach their final size in 3 month or so. You'll be able to go back to work after a week or two. It is advised to restrain from sexual activity or physical efforts for at least 2 weeks, and any activity that may harm the chest for a month. It's important to avoid sunlight to your chest for 6 month to prevent color changes in the breast.
More Tallahassee info...
Tallahassee French
Albert's Provence,Market Square,1415 Timberlane Road.,894-9003.
Chez Pierre,1215 Thomasville Road.,222-0936.
Tallahassee Cajun
Coosh's Bayou Rouge Market & Eatery,2910 Kerry Forest Parkway.,894-4110.
Male Breast ReductionLatest Forum Posts...
- hi, are there any non-surgical procedures that can be done to reduce my man-breasts? it's kinda annoying and embarrassing.
Plastic Surgery News...
- DNA mutations found in a type of non-Hodgkin lymphoma that has a poor prognosis has led researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues to a better understanding of how the cancer develops and how it might be treated. The research findings appear in the March 6, 2008, issue of Science.
- Though treatment of secondary hyperparathyroidism with activated vitamin D analogues is linked to better survival in patients on dialysis., it is unknown if this is the case for patients with chronic kidney disease (CKD) not on dialysis. Therefore, researchers examined the link between oral calcitriol treatment, mortality and the incidence of dialysis in 520 male US veterans (mean age, 69.8 years; 23.5% black) with CKD stages 3 to 5, not yet receiving dialysis (mean estimated GFR 30.8 ml/min). Adjustments were made for age, race, comorbidities, smoking, BP, BMI, use of phosphate binders, estimated GFR, proteinuria, white blood cell count, percentage of lymphocytes, and levels of PTH, calcium, phosphorus, albumin, bicarbonate, and haemoglobin.
In the study, 258 patients received calcitriol, 0.25 to 0.5mcg/d, for a median duration of 2.1 years. The incidence rate ratios for mortality and combined death and dialysis initiation were statistically significantly lower in treated vs. untreated patients (0.35; 95% CI, 0.23 to 0.54; p < 0.001 and 0.46; 0.35 to 0.61, respectively) in the fully adjusted models. These results were consistent across different subgroups.
The researchers conclude that treatment of secondary hyperparathyroidism with calcitriol in patients with CKD stages 3 to 5 not yet on dialysis appears to be linked to statistically significantly greater survival. However, they acknowledge that RCTs are required to verify these observations and examine whether similar associations are seen with different activated vitamin D analogues.